Video
Author(s):
Adana A.M. Llanos, PhD, MPH, discusses how to recognize social determinants of disparities in cancer care.
Adana A.M. Llanos, PhD, MPH, cancer and molecular epidemiologist, Mailman School of Public Health, Columbia University, adjunct associate professor, Rutgers School of Public Health member, American Association for Cancer Research, member, American Public Health Association, member, American Society of Preventive Oncology, member, American Society of Clinical Oncology, member, African-Caribbean Cancer Consortium, discusses how to recognize social determinants of disparities in cancer care.
Although the biology and genetics do play a role with disparities in cancer care, it is important to recognize that social and structural determinants also factor into cancer screening, detections, treatment, and outcomes across different types of cancer, Llanos explains.
Focusing on the various time points throughout this continuum will help achieve more health equity and more equitable outcomes for a greater proportion of patients, Llanos adds. Addressing these disparities needs to be a major goal of long-term research in cancer, Llanos concludes.
Iparomlimab/Tuvonralimab Plus Chemo ± Bevacizumab Yields Responses in Recurrent/Metastatic Cervical Cancer
BMS-986253 Plus Nivolumab/Ipilimumab Fails to Boost Responses in Advanced Melanoma After Prior Anti–PD-(L)1 Therapy
Tremelimumab Plus Paclitaxel Generates Responses in Refractory Metastatic Urothelial Cancer
Pembrolizumab Plus SBRT Fails to Improve Survival in Unresected Stage I/II NSCLC
2 Commerce Drive
Cranbury, NJ 08512